Power Law company profile

Iveric Bio (Formerly Ophthotech)

Biotech & Life Sciences · Princeton, United States · Founded 2007 · IPO 2013 Thoroughbred

A science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases

Valuation

$5.90B

Market cap · 2026

Revenue

$210M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on Iveric Bio (Formerly Ophthotech)'s cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Novo Holdings

SV Health Investors

Series B+ 3 investors entered at this stage

Clarus Ventures

Novo Seeds

Sofinnova Investments

Global footprint

Where Iveric Bio (Formerly Ophthotech) has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States96.8%

🇭🇷 Croatia1.6%

2 countries shown

Web traffic by country

3.1K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Market sentiment

What the market is saying about Iveric Bio (Formerly Ophthotech)

An AI-synthesized read of the highest-engagement posts about Iveric Bio (Formerly Ophthotech) on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Iveric Bio (Formerly Ophthotech) on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles